Penn Oncology Neurosurgery Symposium - Brain Tumors 2014: Bridging Precision Science and Personalized Medicine

Last Modified: March 21, 2014

Share article

Dates: June 6, 2014
Location: Smilow Center for Translational Research Auditorium, Perelman Center for Advanced Medicine, 3400 Civic Center Blvd., Philadelphia, PA 19104

Sponsoring Group: Abramson Cancer Center of the University of Pennsylvania

Web Page URL:

Topics Covered: Minimally Invasive Skull-Base Surgery Radiation Therapy: Proton, Stereotactic Intensity Modulated, Cyber/Gamma Knife Systemic and Targeted Therapies Treatment of Metastatic Brain Tumors Functional Imaging Survivorship: Seizure Management and Neurocognition Anti-angiogenesis Personalized Diagnostics Clinician's Perspective of Precision Medicine Immunotherapy Clinical Trials T-Cell Immunotherapy for Brain Tumors Vaccines New Drug Discovery

Objectives: Upon completion of this symposium, participants should be able to:

  1. Critically assess the advantages of minimally invasive skull base surgery
  2. Describe emerging concepts in the diagnosis and management of brain tumors
  3. Discuss the risks and benefits of proton beam therapy and stereotactic intensity modulated radiation therapy for brain tumors
  4. Describe advances in genome sequencing
  5. Review clinical application of cancer gene panel sequencing
  6. Explain new vaccine therapies tailored to individual patients

Who Should Attend: This symposium is designed for neurosurgeons, neuro-oncologists, neurologists, radiologists, medical oncologists, radiation oncologists, pathologists, neuropsychologists, primary care physicians, oncology nurses, and other healthcare professionals involved in the treatment of patients with brain tumors.

Registration Information: To request a brochure, please contact Mary M. Graham at

Fees: $50 Practicing Physician; $25 non-Penn resident, fellow, nurse, and other healthcare professional; $25 faculty, staff, resident, fellow and/or student of the University of Pennsylvania

Continuing Education: Yes

Audience: HCP

Miscellany: The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Alternate Chromosome 17 Genes Detect True HER2 Status

Sep 29, 2011 - For patients with breast cancer and polysomy 17, the true gene status of human epidermal growth factor receptor 2 (HER2) can be effectively determined by use of additional chromosome 17 fluorescent in situ hybridization studies for Smith-Magenis syndrome, retinoic acid receptor alpha, and tumor protein p53 genes, rather than the HER2-to-centromeric probe ratio, according to a study published online Sept. 26 in the Journal of Clinical Oncology.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More